Already a member?
Sign inBecome part of the foremost online community!
Sign Up NowOr, download the The Glaucoma Community app on your phone
Learn about SpyGlass Pharma’s Phase I/II clinical trial to test its long-term, controlled-release drug implant that could end the need for daily drops.
Ophthalmic biotechnology company SpyGlass Pharma™ has announced the start of its Phase I/II clinical trial to investigate a new long-term, controlled-release drug delivery platform for patients with glaucoma and visually significant cataracts. Learn about the study and what it could mean for you.*
Originally developed at the Sue Anschutz-Rodgers Eye Center at the University of Colorado School of Medicine, the device–a controlled-release introcular lens (IOL)–is designed to be implanted during routine cataract surgery, and to deliver multiple years’ worth of the IOP-lowering medication bimatoprost in patients with open-angle glaucoma or ocular hypertension.
The Phase I/II study will test the safety and efficacy of the SpyGlass IOL with bimatoprost against a control group whose members will receive a standard IOL followed by topical eye drops.
Approval of the Phase I/II study was supported by a first-in-human feasibility study, in which participants consistently experienced a 45% reduction in their IOP on average at nine months.
While this is not the end of the testing phase, researchers are hopeful that the device will spare millions of glaucoma the rigid drug regimens needed to prevent further nerve damage and vision loss.
“Our patient-first mindset is at the core of what we do every day,” said Patrick Mooney, SpyGlass Pharma’s CEO., “and keeps us inspired to drive forward a platform that has the promise of lowering IOP for glaucoma patients without the need to self-administer daily drop therapy.”
“We were pleased to receive clearance from the FDA to initiate our clinical trial,” added Malik Y. Kahook, M.D., SpyGlass’s co-founder and president, “and look forward to advancing this important study.”
*Globe Newswire. (2023, October 31). SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform. BioSpace.
Source: {{articlecontent.article.sourceName}}
Receive daily updated expert-reviewed article summaries. Everything you need to know from discoveries, treatments, and living tips!
Already a Responsum member?
Available for Apple iOS and Android
We've sent a report to our community managers who will take the necessary steps. This member will be removed form your Community Chat and will no longer be able to message you.
Please contact us if you have any questions.
Add Comments
Cancel